- Poly (ADP-ribose) Polymerase (PARP) inhibitors, acting as targeted cancer drugs, are increasingly vital components of modern oncology, particularly in the treatment of various cancers due to their ability to exploit cancer cells' DNA repair deficiencies
- The escalating demand for PARP inhibitors is primarily fueled by the rising global incidence of cancer, particularly ovarian, breast, prostate, and pancreatic cancers. In addition, the growing understanding of cancer genomics and the role of biomarkers in identifying patients who will benefit most from these therapies is a key driver
- North America dominated the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market with the largest revenue share of 44% in 2024, characterized by a high prevalence of target cancers, advanced healthcare infrastructure, significant research and development investments, and favorable regulatory environments. The region has seen substantial growth driven by both established treatments and emerging therapies, with a strong presence of key industry players
- Asia-Pacific is expected to be the fastest growing region in the Poly (ADP-Ribose) Polymerase (PARP) inhibitors market during the forecast period due to increasing urbanization, rising disposable incomes, improving healthcare infrastructure, and a growing cancer burden in countries such as China and India
- Breast Cancer segment dominated the Poly (ADP-Ribose) Polymerase (PARP) inhibitors market with a market share of 48.47% in 2024, driven by the high incidence of the disease, particularly BRCA-mutated breast cancer, and the significant efficacy demonstrated by PARP inhibitors as targeted therapy in this patient population
